Rube­do pulls in $40M Se­ries A to ad­vance atopic der­mati­tis can­di­date tar­get­ing ag­ing cells

Rube­do Life Sci­ences is fur­ther­ing its plan to treat age-re­lat­ed dis­eases by tar­get­ing senes­cent cells with a $40 mil­lion Se­ries A led by Khosla Ven­tures and Ahren In­no­va­tion Cap­i­tal.

The Cal­i­for­nia-based com­pa­ny is ini­tial­ly test­ing its lead can­di­date, dubbed RLS-1496, in atopic der­mati­tis and pso­ri­a­sis, with plans to be­gin a Phase 1 tri­al this year. It’s not re­veal­ing the ex­act tar­get of the drug yet, ac­cord­ing to co-founder and CEO Mar­co Quar­ta, who de­scribed it as nov­el and first-in-class. He added that the der­ma­tol­ogy space is an “en­try point” to then ex­pand the la­bel.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER